Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceIntegrin alpha4beta7 is downregulated on the surfaces of simian immunodeficiency virus SIVmac239-infected cells.Zidovudine and Lamivudine for HIV Infection.A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Evaluation of HIV drug interaction web sites.Simian immunodeficiency virus SIVagm dynamics in African green monkeys.Interactions between alcohol and the antiretroviral medications ritonavir or efavirenzInvestigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceThe nucleoside analogue D-carba T blocks HIV-1 reverse transcription.Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsEfficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 InfectionProdrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.A Validated Stability Indicating RP-HPLC Method for the Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Pharmaceutical Dosage Form.Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride.Aptamer-based Field-Effect Biosensor for Tenofovir Detection.Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms.Synthesis and anti-herpetic activity of phosphoramidate ProTides.Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.Periodic multidrug therapy in a within-host virus model.Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.Hybrid magneto-plasmonic liposomes for multimodal image-guided and brain-targeted HIV treatment.Tenofovir during pregnancy in rats: a novel pathway for programmed hypertension in the offspring.Flexibility-Not just for yoga anymore!Electrospun micelles/drug-loaded nanofibers for time-programmed multi-agent release.An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients.A Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Tenofovir, Emtricitabine, and a Efavirenz and Statistical Approach to Determine the Effect of Variables
P2860
Q27692040-C5EA104D-A6A7-40C4-9F84-B02E73936748Q33990477-B7824F1B-28EE-473C-9D54-ECA2C4B50D14Q34194561-6F20FD85-B81E-48B3-828F-74784CDF2708Q34414539-1B623388-C077-4EEE-AF05-A542A3DF430CQ35562625-12AAC622-315D-434C-9F98-9A29A618A615Q36498208-62D1F374-4483-458E-9D83-BF0EF743D897Q37079827-25C11C96-B968-4230-B530-55B80F089762Q37335799-665DD139-AA67-469F-A4C2-E7718EFA8AA6Q37374652-0B751851-4815-4D04-A1DE-791A7D49539FQ37669191-09054DDB-4490-46CA-8A6C-BD2193FE7FFEQ37705969-1AA80D29-197A-48CE-846D-82E2623D5DDEQ37780687-BF6A773E-4E92-457E-8D8C-684E51E12435Q38833637-1684AE3C-64BD-449D-95FC-9338C0E00FD7Q40128143-0083E4D9-7BA3-440F-BC38-A6B7CB1F5EFBQ40433318-333F1F72-B543-468D-9BBE-A62DFFCEC772Q40654775-475623A8-8018-4E9D-A596-81A85F5390B0Q41813614-C7326B7B-1086-46A8-8715-701ACA6C3AB0Q41871402-F161546A-AFA2-4DA8-9646-19E5BDB264E5Q42017150-DA980F23-638D-43F6-A247-B908E0A0602AQ42037463-BB1AE906-F15C-4BF0-9C5B-A0CC3C8C25BFQ42575236-ECC342B1-1D76-4DFC-9F31-6E262B1DA4F2Q42711775-2AA627E4-6AC1-483D-BB03-E967947027CFQ45037788-ED5BDDE7-3BF5-49C3-9435-B54BB34D7105Q45113899-F18FC133-E267-41CC-8FDB-125004B38CB0Q45364338-7836B975-843F-4B6B-8102-1C7589B6B5A4Q46899237-77689CE1-5E22-4CD6-80F2-032B9E1C0251Q47568994-CDE495B0-2554-4C94-B0EC-CFD69DEC3E7BQ51070026-B817ECDC-B77D-454D-9798-65B8D5D0A40CQ52691809-9AAB6269-B774-4BD3-BD09-E990CF934FB6Q53597147-E5D616F0-FF78-4873-9A77-F9CC52FE1114Q54475515-CBBD9580-CB5C-4565-8607-F2BD8632CEB4Q59000214-4C147FBB-1029-442F-92C2-D145CACEB666
P2860
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@ast
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@en
type
label
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@ast
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@en
prefLabel
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@ast
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@en
P2093
P1476
Tenofovir disoproxil fumarate: ...... he treatment of HIV infection.
@en
P2093
Elizabeth A Stone
Frank J Piacenti
Horatio B Fung
P304
P356
10.1016/S0149-2918(02)80058-3
P577
2002-10-01T00:00:00Z